CG Oncology (CGON) on Monday reported durable long-term outcomes from its phase 3 Bond-003 trial evaluating cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer, or NMIBC, unresponsive to Bacillus Calmette Guerin.
In Cohort C, 75.5% of patients achieved a complete response at any point during the study. At 24 months, 42.3% remained in complete response by Kaplan-Meier estimate, with 97.3% free from progression to muscle-invasive disease and 91.6% of initial responders remaining cystectomy-free.
Early results from Cohort P, in patients with BCG-unresponsive Ta/T1 disease without carcinoma in situ, showed a 90.5% high-grade recurrence-free survival rate at both three and nine months. Treatment was well-tolerated with no grade 3 or higher treatment-related adverse events reported.
The company is continuing to evaluate the therapy for potential regulatory submission.
Shares of CG Oncology rose 34% in recent trading activity.
Price: 30.06, Change: +7.69, Percent Change: +34.38
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。